FDA “Approvable” For Lev’s Cinryze Opens Window For Jerini To Reach Market First

Lev now targets mid-2008 for FDA approval for the C1 inhibitor for hereditary angiodema.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet